Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer

被引：1
|
作者：
Vigneault, E. [1 ]
Morton, G. [2 ]
Perulekar, W. [3 ]
Niazi, T. [4 ]
Springer, G. [5 ]
Barkati, M. [6 ]
Chung, P. [7 ]
Koll, W. [8 ]
Kamran, A. [9 ]
Montreal, M. [3 ]
Ding, K. [3 ]
Loblaw, A. [2 ]
机构：
[1] CHU Quebec, Hotel Dieu Quebec, Radiat Oncol & Res Ctr, Quebec City, PQ, Canada
[2] Odette Canc Ctr, Radiat Oncol, Toronto, ON, Canada
[3] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[4] Mc Gill Jewish Gen Hosp, Dept Radiat Oncol, Montreal, PQ, Canada
[5] Windsor Reg Hosp, Radiat Oncol, Windsor, ON, Canada
[6] CHUM Hop Notre Dame, Radiat Oncol, Montreal, PQ, Canada
[7] Univ Hlth Network, Princess Margaret Canc Ctr, Radiat Oncol, Toronto, ON, Canada
[8] Lakeridge Hosp, Radiat Oncol, Oshawa, ON, Canada
[9] Dr H Bliss Murphy Canc Ctr, Radiat Oncol, St John, NF, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2017年 / 123卷
关键词：
D O I：
10.1016/S0167-8140(17)32136-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-1774
引用
收藏
页码：S975 / S976
页数：2
相关论文
共 50 条
  • [41] Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study
    Alayed, Yasir
    Loblaw, Andrew
    Chu, William
    Al-Hanaqta, Motasem
    Chiang, Andrew
    Jain, Suneil
    Chung, Hans
    Vesprini, Danny
    Morton, Gerard
    Ravi, Ananth
    Davidson, Melanie
    Deabreu, Andrea
    Mamedov, Alexandre
    Zhang, Liying
    Erler, Darby
    Cheung, Patrick
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (05): : 1066 - 1073
  • [42] FOCAL ABLATION VERSUS RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: INTERIM ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL
    Baco, Eduard
    Berg, Rolf Eigil
    Eggesbo, Heidi B.
    Rud, Erik
    JOURNAL OF UROLOGY, 2021, 206 : E815 - E815
  • [43] Single-Dose SBRT for Intermediate-risk prostate cancer: Early results from a randomized trial.
    Greco, C.
    Pimentel, N.
    Pares, O.
    Possanzini, M.
    Louro, V.
    Morales, X.
    Viera, S.
    Stroom, J.
    Mateus, D.
    Nunes, B.
    Fuks, Z.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S329 - S329
  • [44] Re: Prospective Randomized Phase 2 Trial of Intensity Modulated Radiation Therapy with or without Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Intermediate-Risk Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2015, 193 (03): : 847 - 847
  • [45] Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study
    Kaplan, Irving
    Bubley, Glenn J.
    Bhatt, Rupal S.
    Taplin, Mary-Ellen
    Dowling, Shanna
    Mahoney, Kathleen
    Werner, E.
    Nguyen, Paul
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (05): : 1416 - 1422
  • [46] Hypofractionated IGRT for prostate cancer: first report on toxicity of a phase III randomized trial
    Mazzeo, E.
    Bruni, A.
    Iotti, C.
    Frezza, G.
    Meduri, B.
    Guidi, G.
    Vigo, F.
    Vicini, R.
    Vernaleone, M.
    Ciabatti, S.
    Cenacchi, E.
    Stefanelli, A.
    Miranda, G.
    Diquattro, S.
    Romeo, A.
    D'Amico, R.
    Bertoni, F.
    Lohr, F.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S150 - S151
  • [47] Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
    Nabid, Abdenour
    Souhami, Luis
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 166 - 167
  • [48] IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer
    Graff, Pierre
    Portalez, Daniel
    Lusque, Amelie
    Brun, Thomas
    Aziza, Richard
    Khalifa, Jonathan
    Roumiguie, Mathieu
    Ranty, Marie-Laure Quintyn
    Filleron, Thomas
    Bachaud, Jean-Marc
    Malavaud, Bernard
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (04): : 903 - 911
  • [49] Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial
    Miki, Kenta
    Kiba, Takayoshi
    Sasaki, Hiroshi
    Kido, Masahito
    Aoki, Manabu
    Takahashi, Hiroyuki
    Miyakoda, Keiko
    Dokiya, Takushi
    Yamanaka, Hidetoshi
    Fukushima, Masanori
    Egawa, Shin
    BMC CANCER, 2010, 10 : 572
  • [50] Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial
    Kenta Miki
    Takayoshi Kiba
    Hiroshi Sasaki
    Masahito Kido
    Manabu Aoki
    Hiroyuki Takahashi
    Keiko Miyakoda
    Takushi Dokiya
    Hidetoshi Yamanaka
    Masanori Fukushima
    Shin Egawa
    BMC Cancer, 10
12345